These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 39206838)

  • 1. Small HBV surface antigen drives regorafenib resistance in HCC via KIAA1429-dependent m6A modification of CCR9.
    Lv Z; Liu L; You J; Zhou P; Su Y; Zhao K; Zhang J; Zhu F
    J Med Virol; 2024 Sep; 96(9):e29894. PubMed ID: 39206838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B Virus Small Envelope Protein Promotes Hepatocellular Carcinoma Angiogenesis via Endoplasmic Reticulum Stress Signaling To Upregulate the Expression of Vascular Endothelial Growth Factor A.
    Wu SX; Ye SS; Hong YX; Chen Y; Wang B; Lin XJ; Lin X
    J Virol; 2022 Feb; 96(4):e0197521. PubMed ID: 34910612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHOP regulated by METTL14-m6A affects cell cycle arrest and regorafenib sensitivity in HCC cells.
    Pan Y; You B; Zhao X; Zhang S; Li W
    BMC Cancer; 2024 Apr; 24(1):525. PubMed ID: 38664644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small hepatitis B virus surface antigen promotes malignant progression of hepatocellular carcinoma via endoplasmic reticulum stress-induced FGF19/JAK2/STAT3 signaling.
    Wu S; Ye S; Lin X; Chen Y; Zhang Y; Jing Z; Liu W; Chen W; Lin X; Lin X
    Cancer Lett; 2021 Feb; 499():175-187. PubMed ID: 33249195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B Virus-Mediated m6A Demethylation Increases Hepatocellular Carcinoma Stemness and Immune Escape.
    Meng Y; Shu Z; Wang X; Hong L; Wang B; Jiang J; He K; Cao Q; Shi F; Wang H; Gong L; Diao H
    Mol Cancer Res; 2024 Jul; 22(7):642-655. PubMed ID: 38546386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AC099850.3 promotes HBV-HCC cell proliferation and invasion through regulating CD276: a novel strategy for sorafenib and immune checkpoint combination therapy.
    He A; Huang Z; Feng Q; Zhang S; Li F; Li D; Lu H; Wang J
    J Transl Med; 2024 Aug; 22(1):809. PubMed ID: 39217342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
    J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.
    Teufel M; Seidel H; Köchert K; Meinhardt G; Finn RS; Llovet JM; Bruix J
    Gastroenterology; 2019 May; 156(6):1731-1741. PubMed ID: 30738047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus mRNAs functionally sequester let-7a and enhance hepatocellular carcinoma.
    Deng M; Hou J; Hu J; Wang S; Chen M; Chen L; Ju Y; Li C; Meng S
    Cancer Lett; 2016 Dec; 383(1):62-72. PubMed ID: 27693636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis.
    Qu S; Jin L; Huang H; Lin J; Gao W; Zeng Z
    BMC Cancer; 2021 Jun; 21(1):686. PubMed ID: 34112124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOD1 inhibition enhances sorafenib efficacy in HBV-related hepatocellular carcinoma by modulating PI3K/Akt/mTOR pathway and ROS-mediated cell death.
    Lee J; Kim J; Lee R; Lee E; An HI; Kwon YJ; Jin H; Pack CG; Kim I; Yoon YI; Park GC; Jwa EK; Kwon JH; Namgoong JM; Song GW; Hwang S; Tak E; Lee SG
    J Cell Mol Med; 2024 Jul; 28(14):e18533. PubMed ID: 39034442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linc00152 promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma.
    Deng X; Zhao XF; Liang XQ; Chen R; Pan YF; Liang J
    Biomed Pharmacother; 2017 Jun; 90():100-108. PubMed ID: 28343069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N
    Rao X; Lai L; Li X; Wang L; Li A; Yang Q
    IUBMB Life; 2021 Feb; 73(2):408-417. PubMed ID: 33372396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cumulative antitumor effects of regorafenib and radiotherapy in hepatocellular carcinoma.
    Kuang S; Zhang J; Huang N; Zhang J; Chen B; Wang L; Liu M
    Mol Carcinog; 2024 Sep; 63(9):1738-1749. PubMed ID: 38837427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of hepatitis B virus surface antigen, hepatitis C virus expression in hepatocellular carcinoma and pericarcinomatous tissues.
    Xuan SY; Xin YN; Chen H; Shi GJ; Guan HS; Li Y
    World J Gastroenterol; 2007 Mar; 13(12):1870-4. PubMed ID: 17465484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COL5A2 drives regorafenib resistance-induced metastatic phenotype via reducing LIFR expression in hepatocellular carcinoma.
    Zhang S; Xue X; Chen F; Yang Y; Zhang N; Chen Y; Wu W; Wang J; Zheng N
    Acta Biochim Biophys Sin (Shanghai); 2024 May; 56(7):997-1010. PubMed ID: 38818582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway.
    Wang J; Zhang N; Han Q; Lu W; Wang L; Yang D; Zheng M; Zhang Z; Liu H; Lee TH; Zhou XZ; Lu KP
    Cancer Lett; 2019 Mar; 444():82-93. PubMed ID: 30583078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9-mediated knockout of HBsAg inhibits proliferation and tumorigenicity of HBV-positive hepatocellular carcinoma cells.
    Song J; Zhang X; Ge Q; Yuan C; Chu L; Liang HF; Liao Z; Liu Q; Zhang Z; Zhang B
    J Cell Biochem; 2018 Nov; 119(10):8419-8431. PubMed ID: 29904948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein.
    Zhang S; Gao S; Zhao M; Liu Y; Bu Y; Jiang Q; Zhao Q; Ye L; Zhang X
    Cancer Lett; 2017 Apr; 392():94-104. PubMed ID: 28192212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma.
    Dai Z; Wang X; Peng R; Zhang B; Han Q; Lin J; Wang J; Lin J; Jiang M; Liu H; Lee TH; Lu KP; Zheng M
    Cancer Lett; 2022 Jan; 524():161-171. PubMed ID: 34687791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.